logo-loader

Tiziana Life Sciences files patent application for its novel coronavirus treatment technology

Published: 02:56 09 Apr 2020 EDT

Tiziana Life Sciences (LON:TILS) chairman and founder Gabriele Cerrone talks Proactive London's Andrew Scott through the company's update this morning which he describes as an important step in finding a solution to the current pandemic. It's filed a patent around the direct delivery method of Anti-Interlukin-6-Receptor Monoclonal Antibodies into the lungs using a handheld inhaler or nebuliser. Cerrone adds that the technology could also be applicable for use with other FDA approved mAbs and drugs.

Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced some fresh clinical results from its work in treating non-active secondary progressive...

on 10/16/2023